The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines (Lundbeck)

European Commission fines Lundbeck and other pharmaceutical companies for delaying market entry of generic medicines* On 19 June 2013 the European Commission issued a press release stating that it had imposed fines in the amount of € 93,8 million on Lundbeck (a Danish pharmaceutical company) and € 52,2 million on manufacturers of other generic medicines that were producing a cheaper and generic version of Lundbeck’s brand-drug citalopram. The generics manufacturers were notably Alpharma (now part of

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Authors

Quotation

Gabriele Accardo, Anthony Reda, The EU Commission fines pharmaceutical companies for delaying market entry of generic medicines (Lundbeck), 19 June 2013, e-Competitions Bulletin Competition in the Pharmaceutical sector, Art. N° 57743

Visites 251

All issues

  • Latest News issue 
  • All News issues
  • Latest Special issue 
  • All Special issues